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Influenza A virus segment 2 is known to encode two polypeptides in overlapping open reading frames: PB1,
the polymerase, and PB1-F2, a proapoptotic virulence factor. We show that a third major polypeptide is
synthesized from PB1 mRNA via differential AUG codon usage. PB1 codon 40 directs translation of an
N-terminally truncated version of the polypeptide (N40) that lacks transcriptase function but nevertheless
interacts with PB2 and the polymerase complex in the cellular environment. Importantly, the expression of
N40, PB1-F2, and PB1 are interdependent, and certain mutations previously used to ablate PB1-F2 production
affected N40 accumulation. Removal of the PB1-F2 AUG upregulated N40 synthesis, while truncating PB1-F2
after codon 8 (with a concomitant M40I change in PB1) abolished N40 expression. A virus lacking both N40
and PB1-F2 replicated normally. However, viruses that did not express N40 but retained an intact PB1-F2 gene
overexpressed PB1 early in infection and replicated slowly in tissue culture. Thus, the influenza A virus
proteome includes a 12th primary translation product that (similarly to PB1-F2) is nonessential for virus
viability but whose loss, in particular genetic backgrounds, is detrimental to virus replication.
Influenza A virus (IAV) is a major pathogen that infects a
broad variety of homeothermic vertebrates, including humans
and domesticated animal species such as chickens, swine, and
horses (27). Individual strains of IAV tend to be specific to a
single host species and, although they may infect alternative
hosts, this is generally a sporadic, inefficient process until ad-
aptation to the new host occurs (26). IAVs also vary widely in
pathogenicity, with high virulence often being associated with
cross-species transmission events. An extreme example of this
in humans is the contrasting mortality rates resulting from
infection with human-adapted H1N1 viruses (0.1% case fa-
tality) and current avian H5N1 strains (60%) (36, 40; http:
//www.who.int/csr/disease/avian_influenza/country/en/).
The IAV genome is carried on eight segments of negative-
sense RNA. Host range and pathogenicity are polygenic traits,
but it is well established that segment 2 plays an important role
(3, 4). In part, this reflects the essential functions of PB1, the
primary protein product of the segment. PB1 is the core sub-
unit of the viral RNA-dependent RNA polymerase, which is
responsible for transcription and replication of the virus ge-
nome (14). However, nearly 20 years after the first complete
nucleotide sequence of segment 2 was published (6), a second
polypeptide made from segment 2 mRNA was discovered (9).
Most, but not all strains of IAV express a small (up to 90-
amino-acid) polypeptide (designated PB1-F2) from an over-
lapping open reading frame (ORF) embedded entirely within
the 5 end of the PB1 cistron (8, 9, 51). PB1-F2 localizes to
mitochondria through its C-terminal region and induces apop-
tosis in certain cell types (9, 17, 47, 49). The proapoptotic
effects of overexpressed PB1-F2 suggested the hypothesis that
it is a virulence factor (9), and several studies have correlated
its loss of expression and/or sequence polymorphisms with
alterations to virus pathogenicity (10, 31, 50). However, no
evidence has been presented to date to show that the increased
pathogenicity observed in vivo is caused by PB1-F2 induced
apoptosis. It has also been suggested that PB1-F2 influences
the activity and intracellular localization of PB1 itself through
an interaction occurring in the nuclei of cells (30).
The expression of PB1-F2 is thought to occur by leaky ribo-
somal scanning past three upstream AUG codons (9). Al-
though not formally tested, this is plausible since neither the
PB1 AUG codon nor those of two intervening short ORFs are
set in strong Kozak translation initiation contexts (24), whereas
the AUG of PB1-F2 is (Fig. 1A). It has also been proposed that
shorter PB1-F2 polypeptides are synthesized from one or more
AUG codons further downstream of the PB1-F2 start codon
(50), but for this to occur by leaky scanning would require the
unlikely scenario of ribosomes bypassing a minimum of three
further AUG codons with strong initiation contexts to initiate
on AUGs with moderate contexts (Fig. 1A). Thus, there are
interesting and (given the significance of PB1 and PB1-F2 to
IAV pathogenicity) important unresolved questions regarding
the regulation of gene expression from segment 2. Toward this,
we show here that a third major polypeptide species is trans-
lated from segment 2 mRNA; PB1 N40, an N-terminally trun-
cated and functionally distinct variant of PB1. Furthermore, we
find that, whereas N40 is not essential for virus replication in
cultured cells, the expression of PB1, PB1 N40, and PB1-F2 is
interdependent, and the absence of N40 in the presence of an
intact PB1-F2 ORF leads to slower virus replication kinetics.
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MATERIALS AND METHODS
Plasmids, antisera, and viruses. Plasmids pcDNA-PB2, -PA, and -NP, con-
taining cDNA copies of the influenza A/PR/8/34 (PR8) genes have been previ-
ously described (32). Plasmids pPolI-Flu-ffLuc containing an influenza virus-
based luciferase minireplicon vRNA under the control of the human RNA
polymerase I promoter and pcDNA mMx1 containing the murine Mx1 gene were
provided by Laurence Tiley (5). Plasmid pcDNA-N40, containing a cDNA copy
of PR8 segment 2 (accession no. EF467819) lacking start codons upstream of
AUG 5 was constructed by PCR to insert bp 121 to 2307 of segment 2 into the
XhoI/XbaI sites of pcDNA3. Plasmids pcDNA PB1-, PB2-, and PA-GFP were
provided by Ervin Fodor (16). pEGFP-TAP, encoding a green fluorescent pro-
tein (GFP) fusion with the human mRNA export Tip-associated protein was
supplied by Adrian Whitehouse (45). Dual promoter reverse genetics plasmids
for PR8 segments 1 and 3 to 8 were given by Ron Fouchier (11). A similar
construct for segment 2 was generated by subcloning the human polymerase I
promoter, viral sequences (originally cloned from the NIBSC strain of PR8), and
hepatitis delta ribozyme sequence from a previously described plasmid (44) into
the pcDNA3 multicloning site. Sequence analysis of this plasmid showed the
influenza gene to be identical to the clone reported by (11) with the exception of
two nucleotide changes (T1204C and T1434C). Other mutants had additional
substitutions introduced by site-directed mutagenesis as follows: F2-8, G144A;
F2-57, G291A and T309A; AUG, A115T, G116C, C117A, and T120C; M40L,
A142T; and M40I, G144T. The predicted phenotypic effects of these mutations
on the segment 2 ORFs are summarized in Table 1. All plasmids were sequence
verified.
Mouse monoclonal anti-PB1 clone 10.4 (directed against an epitope contained
between residues 44 and 69) and a rabbit polyclonal serum raised against a
peptide corresponding to amino acids 740 to 757 of PB1 were generously pro-
vided by Mark Krystal. Rabbit polyclonal anti-PB1 serum V19 raised against
amino acids 50 to 370 of PR8 PB1, as well as similar anti-PA, anti-PB2, and
anti-NP (2915) sera, have been previously described (13, 22). A rabbit antiserum
FIG. 1. Expression of multiple protein species from IAV segment 2. (A) Diagram of the 5 end of segment 2 mRNA. ORFs in the three reading
frames are indicated by boxes. AUG codons are color coded according to the relative strength of their Kozak consensus (green  strong, 3A/G,
4G; amber intermediate,3A/G or 4G; red weak,3U,4U), and those that initiate identified polypeptides are indicated. (B) Detection
of a minor PB1 species from infected cells. [35S]methionine-labeled lysate from MDCK cells infected (lanes I) or mock infected (lanes M) with
Cambridge PR8 virus were immunoprecipitated with anti-PB1 V19, anti-PA V35, or anti-PB2 V28 as indicated and analyzed by SDS-PAGE and
autoradiography in parallel with a radiolabeled in vitro translation reaction of WT segment 2 (in lane R, a lower exposure of the same track was
used). (C) Lysates from cells infected (or mock infected) with the indicated panel of viruses, as well as in vitro-translated N40 were analyzed by
Western blotting for PB1 with anti-PB1 V19 serum. (D) Aliquots of in vitro translation reactions programmed with the indicated plasmids (lane
VOC [vector only control]) were analyzed by SDS-PAGE and autoradiography. (E) Lysates from 293T cells transfected with the indicated plasmids
(pDUAL; empty vector control) were analyzed by SDS-PAGE and Western blotting with anti-PB1 MAb 10.4 (top panel) or anti-PB1-F2
C-terminal specific serum (bottom panel). The migration of molecular mass markers (in kilodaltons), as well as specified polypeptides, is indicated.
TABLE 1. Phenotypic summary of segment 2 mutants
Virus
Predicted structure of
ORFs Major phenotype(s) Replicationkinetics
PB1 PB1-F2 N40
F2-8 M40I 8 Null WT
F2-57 WT 57 WT WT




M40L M40L WT Null Early increase in PB1 Delayed
M40I M40I W9L Null Early increase in PB1 Delayed
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to the C terminus of the PB1-F2 protein was kindly provided by Jonathan
Yewdell. Rat monoclonal anti-tubulin YL1/2 was purchased from Serotec. IR800
and IR680 dye-conjugated anti-rabbit immunoglobulin G (IgG) and anti-mouse
IgG sera were purchased from LiCor, while IR680 dye conjugated anti-rat IgG
was purchased from Invitrogen. Alexa 594-conjugated anti-mouse IgG and flu-
orescein isothiocyanate (FITC)-conjugated anti-rabbit IgG were purchased from
Invitrogen and Dako, respectively.
Nonrecombinant viruses PR8 (H1N1, Cambridge lineage) A/Udorn/72
(Udorn; H3N2) A/USSR/77 (USSR; H1N1) were sourced from the Division of
Virology’s collection of influenza viruses (15, 41). A/Eq/Newmarket/11/03 (Eq/
Nkt; H3N8) was kindly provided by Janet Daly, while A/Dk/Singapore/5/97
(Dk/Sing; H5N3) was originally obtained from the Health Protection Agency
collection held at Colindale (42). Recombinant PR8 viruses were produced by
transfection of plasmids into 293T cells as previously described (22) and passaged
once in MDCKs and then once in 8-day-old embryonated eggs. Segment 2 was
sequenced from each virus stock to ensure the presence of the correct mutations.
Virus titers were determined by plaque assay in MDCK cells, and plaque sizes
were measured as previously described (22).
Protein analyses. Coupled in vitro transcription-translation reactions were
carried out in rabbit reticulocyte lysate using the Promega TNT system according
to the manufacturer’s instructions. Metabolically labeled infected cell lysates
were generated and subjected to immunoprecipitation as previously de-
scribed (13, 15). Sodium dodecyl sulfate-polyacrylamide gel electrophoresis
(SDS-PAGE) and Western blots were performed according to standard pro-
cedures. Blots were imaged by using infrared fluorescence of appropriately
tagged secondary antibodies and quantified by using a LiCOR Odyssey scan-
ner and software. Influenza RNP reconstitution assays were carried out as
previously described (32), except that a synthetic vRNA encoding luciferase
was used as the minigenome.
Microscopy. Fluorescence microscopy of cells fixed with 4% formaldehyde was
carried out as previously described (15, 41). Samples were imaged by using a
Leica TCS SP confocal microscope. Postcapture processing of images to allow
daylight visualization and reproduction was applied equally to each experiment
by using Adobe Photoshop. For FRAP analysis, cells were maintained at 37°C in
CO2 independent Leibovitz L-15 medium (Gibco). Images were captured on a
Zeiss LSM 510 confocal microscope using a 63 objective and a digital zoom
factor of 5. GFP was excited using the 488-nm laser line of a 30-mW Ar laser
running at 6.1 A and 1% output. Photobleaching was performed on a 1.4-	m2
bleach window at 100% laser output. Five prebleach and seventy postbleach
images were collected at 0.39-s intervals. Fluorescence intensities of regions of
interest were obtained using the LSM510 software. After correction for back-
ground fluorescence and acquisition photobleaching, diffusion coefficient (DC)
values were calculated by using an adaptation of classical FRAP analysis (2) as
described elsewhere (25; E. M. Loucaides et al., unpublished data).
RESULTS
Polypeptide expression patterns from IAV segment 2. PB1-F2
expression has been postulated to occur by translation initia-
tion at AUG4 on the PB1 mRNA (9), after scanning ribosomes
have bypassed the suboptimal context AUGs 1 to 3 (Fig. 1A).
Use of one or more of AUGs 7 to 9 to give rise to C-terminal
PB1-F2 polypeptides has also been suggested (50). Inspection
of the influenza PR8 virus segment 2 sequence shows two
intervening AUG codons that are both in strong Kozak initi-
ation consensus sequences (Fig. 1A; AUGs 5 and 6), which
must therefore also be considered candidates for translation
initiation. We considered AUG6 to be of less potential signif-
icance since it accesses a short ORF in reading frame 3 (Fig.
1A) and it is not well conserved in IAV, being present in only
around one-third of virus isolates (18). In contrast, AUG5 is
very highly conserved among natural virus isolates, being ab-
sent from only 26 of 7411 publicly accessible (GenBank) PB1
sequences (9, 18) (Table 2). This AUG is 115 nucleotides
downstream of AUG1 and 21 nucleotides downstream of
AUG4. It is in the same reading frame as AUG1, and its use as
an initiation codon would be predicted to give rise to a protein
product identical to PB1 except for the lack of the first 39
amino acids (termed here PB1 N40).
Therefore, we first investigated whether PB1 N40 was pro-
duced in cells infected with IAV. Radiolabeled cell lysates
from MDCK cells infected (or mock infected) with PR8 virus
were treated with SDS to disrupt noncovalent protein-protein
interactions and then immunoprecipitated with monospecific
serum against the IAV P proteins before analysis by SDS-
PAGE and autoradiography. In parallel, a plasmid containing
a cDNA clone of wild-type (WT) PR8 segment 2 was in vitro
translated in rabbit reticulocyte lysate to provide a marker.
Polypeptides of the expected size for full-length PB1, PB2, and
PA were apparent in the samples immunoprecipitated from
infected cells (Fig. 1B, lanes 2, 4, and 6). However, while single
TABLE 2. IAV isolates lacking the PB1-N40 AUG codon
Virus Accession no. Subtype PB1 codon 40a Length of PB1-F2 ORF
b
(codons)
A/chicken/NJ/17169/1993 EU743092 H5N2 M40L 79*
A/chicken/Yokohama/aq144/2001 AB256744 H9N2 M40L 79
A/swine/Alberta/56626/03 DQ280198 H1N1 M40I 11†
A/chicken/Chis/15224/1997 CY006041 H5N2 M40I 0
A/duck/Germany/1215/1973 CY014715 H2N3 M40I 8
A/Ontario/1252/2007 EU399757 H3N2 M40I 8
A/swine/Saitama/1996 AB434414 H1N2 M40I 8
A/chicken/Laos/P0171/2007 CY034718 H5N1 M40I 8
A/northern pintail/Alaska/44204-075/2006 EU557446 H3N8 M40I 90†
A/Chicken/Hong Kong/739/94 AF156422 H9N2 M40I 8
A/partridge/Shantou/1913/2004 EU050495 H6N2 M40I 8
A/chukkar/Shantou/1530/2005 EU050533 H6N1 M40I 8
A/silky chicken/Shantou/1826/2004c CY023302 H9N2 M40I 8
A/chicken/Hunan/774/2002 CY023766 H9N2 M40I 8
A/turkey/Shantou/1915/2004 EU050496 H6N2 M40I 8
A/chukkar/Shantou/89/2005 EU050528 H6N1 M40I 8
A/silky chicken/Korea/S3/03 AY862694 H9N2 M40I 8
a Substitution at PB1 codon 40.
b *, This ORF has a mutation in the mitochondrial targeting sequence; †, these ORFs also possess the W9L mutation.
c Nine related sequences from other H9N2 viruses are not shown (46).
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polypeptide species were precipitated by anti-PB2 or anti-PA
sera, two proteins were apparent in the PB1 sample (lane 2).
Western blotting of the immunoprecipitates confirmed that
both species were PB1 related (data not shown). Two major
polypeptide species were also produced when segment 2 was in
vitro translated, and these comigrated with the products from
infected cells (lane 1). To investigate whether production of a
shorter form of PB1 was a consistent feature of IAV, MDCK
cells were infected with a panel of human, avian, and equine
viruses, and the cell lysates were examined by immunoblotting.
In all cases, as well as a predominant PB1 polypeptide, a
shorter protein product was also detected, which, furthermore,
comigrated with an in vitro-translated N40 polypeptide (Fig.
1C, compare lanes 2 to 7 with lane 8).
We hypothesized that, like PB1-F2, N40 is expressed by
leaky ribosomal scanning. This hypothesis predicts that some
of the mutations used by previous studies to ablate PB1-F2
expression will affect N40 expression. To date, all such studies
have used (either wholly or in part) viruses in which the
PB1-F2 AUG has been mutated (AUG) (9, 30, 31, 50), which
would be predicted to increase use of the downstream AUG5
and hence increase N40 expression levels. In addition, two
studies used the strategy of altering codon W9 of PB1-F2 to a
stop codon (F2-8), coincidentally introducing a nonsynony-
mous M40I mutation in PB1 and removing the N40 initiation
codon (9, 50). Accordingly, we introduced AUG and F2-8
mutations into a cDNA copy of PR8 segment 2 cloned into a
bidirectional reverse genetics plasmid. Three further mutants
were created as controls. First, in the F2-57 construct, codons
58 and 64 of PB1-F2 were altered to termination codons
through changes that are silent in the PB1 ORF. This construct
mimics the truncated PB1-F2 found in many human H1N1
viruses from 1947 onward (8, 51); these mutations were not
predicted to alter N40 expression. Finally, two additional mu-
tations were made to examine the interdependence of N40 and
PB1-F2 expression. The first of these, M40L, destroys the N40
AUG but is silent in the F2 ORF. The second also alters
AUG5 through an M40I change as in the F2-8 mutant. How-
ever, rather than introducing a stop codon (as in F2-8), a W9L
mutation is introduced into PB1-F2. These changes to segment
2 ORFs are summarized in Table 1.
As a first test of whether AUG5 was used to initiate synthesis
of a shorter form of PB1, the WT and mutated plasmids were
in vitro translated. As before, WT segment 2 produced two
polypeptides, of which the smaller form comigrated with in
vitro-translated N40 (Fig. 1D, lanes 2 and 8). The F2-57 mu-
tant directed translation of products similar to those of the WT
gene, but plasmids lacking AUG5 (F2-8, M40L, and M40I)
produced only a single polypeptide of the expected size for
full-length PB1 (lanes 3, 6, and 7). In the case of the AUG
construct, the shorter species was translated in greater abun-
dance than full-length PB1 (lane 5). To confirm these results
and verify the PB1-F2 status of these mutants, the plasmids
were transiently transfected into 293T cells, and cell lysates
were examined by immunoblotting with antisera to PB1 and
PB1-F2. In agreement with the in vitro results, plasmids con-
taining WT and F2-57 segment 2 produced both full-length
and, in lesser abundance, shorter forms of PB1 (Fig. 1E, upper
panel, lanes 2 and 4), but only the full-length protein was
produced from F2-8, M40L, or M40I plasmids (lanes 3, 6, and
7). Again, the AUG plasmid expressed higher levels of the
truncated PB1 polypeptide (lane 5). As predicted, an anti-
serum raised against the C terminus of PB1-F2 detected syn-
thesis of the protein in cells transfected with WT, M40I, and
M40L plasmids (Fig. 1E, lower panel, lanes 2, 6, and 7), al-
though the M40I plasmid expressed somewhat lower levels,
perhaps suggesting that the W9L mutation in PB1-F2 may have
destabilized the protein. No specific PB1-F2 signal was de-
tected from segment 2 plasmids with the F2-8, F2-57, or
AUG mutations (Fig. 1E, lower panel, lanes 3 to 5), although
since the truncation of the PB1-F2 ORF in the F2-57 construct
would prevent expression of the antibody epitope, we cannot
exclude that a short 57-amino-acid PB1-F2 protein is made in
this case. Conversely, we did not detect production of N-ter-
minally truncated PB1-F2 polypeptides produced from AUGs
7 to 9, as seen in a previous study (50). Overall, these experi-
ments strongly supported the hypothesis that AUG5 is used to
direct translation of a shorter form of PB1 (named here as
N40), as well as demonstrating that mutations affecting PB1-F2
expression have the potential to alter its expression.
In order to investigate the function of N40 and to examine
the effect of altering the relative levels of segment 2 gene
products during infection, reverse genetics was used to intro-
duce the segment 2 mutations described above into PR8 virus.
Viruses were rescued by transfection of eight bidirectional
plasmids into 293T cells, and stocks were amplified in MDCK
cells and embryonated eggs. Initially, expression of segment 2
polypeptides was analyzed at 8 h postinfection (p.i.) in MDCK
cells by immunoblotting for PB1 and PB1-F2. Mirroring the
plasmid expression data, PB1-F2 was only expressed in cells
infected with the M40L, M40I, and WT viruses (Fig. 2A, lower
panel). As before (Fig. 1B and C), a monoclonal antibody
recognizing an epitope in amino acids 44 to 69 of PB1 detected
two forms of the protein from cells infected with WT PR8
virus: a predominant species of the expected size for the full-
length protein and a lower-abundance, slightly smaller species
(Fig. 2A, top panel, lane 2). Again, in agreement with the
plasmid-based data, this pattern was unchanged with the F2-57
virus (lane 4), but viruses F2-8, M40L, and M40I failed to
express N40 (lanes 3, 6, and 7), while the AUG virus pro-
duced equivalent amounts of short and long forms of PB1
(lane 5). To further probe the origin of the short form of PB1,
a duplicate filter was probed with an antibody raised against
the C-terminal 18 residues of PB1. The N40 polypeptide was
detected in lysates from cells infected with WT, F2-57, and
AUG viruses (Fig. 2A, middle panel), indicating that the
protein has an intact C terminus.
Overall, therefore, the variation in abundance of the lower-
molecular-weight PB1 N40 species according to the presence,
absence, or context of AUG5 both in DNA-based and authen-
tic viral expression settings, coupled with its reactivity with
antibodies directed against PB1 residues 44 to 69 and residues
740 to 757 provides strong evidence that, in addition to AUGs
1 and 4, AUG5 is also used for translation initiation in segment
2 mRNA. Next, we examined the kinetics of its expression.
Low overall amounts of PB1 at 4 h p.i. made detection of the
N40 form difficult, except in the case of the AUG virus, where
it was present in higher abundance than the full-length protein
(Fig. 2C, upper panels, lane 5). At a late time point of 20 h p.i.,
N40 was visible in all samples from viruses with an intact
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AUG5 (Fig. 2C, lower panels) but in apparently lower relative
amounts to the full-length protein. In confirmation of this,
quantification of replicate experiments showed that, whereas
N40 represented ca. 6 to 10% of the total PB1 polypeptides in
cells infected with WT and F2-57 viruses at 8 h p.i., by 20 h p.i.
this level had dropped to ca. 2% (Fig. 2B). Similarly, in the
case of the AUG virus, where N40 was more abundant than
WT PB1 at 8 h p.i., by 20 h p.i. it had fallen to ca. 20% of the
total PB1 protein (Fig. 2B).
During these infections, the accumulation of full-length PB1
in F2-8 and F2-57 virus-infected cells appeared near normal
(Fig. 2A, C, and D). However, compared to WT virus, an early
delay in PB1 expression in AUG-infected cells and, con-
versely, increased early expression of PB1 in M40L- and M40I-
infected cells was apparent (Fig. 2C, upper panels, compare
lane 2 with lanes 5 to 7). Quantification confirmed a reproduc-
ible difference, with average PB1 levels in AUG virus-in-
fected cells at 4 h p.i. reduced by nearly threefold compared to
WT virus, whereas those in M40L- and M40I -infected cells
were raised by more than 1.5- and 3-fold, respectively (Fig.
2D). However, as infection proceeded, the differences became
less marked, with PB1 levels for all mutant viruses at 20 h p.i.
appearing near normal. When PB1-F2 expression was quanti-
fied, no significant accumulation was seen in cells infected with
the F2-8, F2-57, and AUG viruses (Fig. 2E), as expected. The
levels of the protein were near normal in the case of virus
M40L but reduced more than twofold for virus M40I (Fig. 2E).
In summary, these data show that N40 is expressed during
FIG. 2. Expression of segment 2 polypeptides in virus-infected cells. MDCK cells were infected (or mock infected) with the panel of viruses
as labeled, and cell lysates were obtained at various times p.i. (panel A, 8 h p.i.; panels C to E, as labeled) analyzed by Western blotting for the
indicated polypeptides. Representative experiments are shown in panels A and C. (B, D, and E) The accumulation of the indicated polypeptides
was quantified. The means
 the standard errors of the mean (SEM) of four independent experiments using two independently rescued virus stocks
are plotted in panels B and D, while the data in panel E reflect the means and ranges of two independent experiments.
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infection with WT IAV where, especially at earlier times p.i., it
provides an appreciable fraction of the total PB1-related
polypeptides. Furthermore, its expression is altered by muta-
tions previously used by others to abolish PB1-F2 production.
Importantly, a complex interplay of expression of the three
segment 2 gene products was evident, since the AUG virus
that expressed elevated levels of N40 in the absence of PB1-F2,
displayed reduced accumulation of PB1 at early time points p.i.
In contrast, N40 null viruses that also expressed PB1-F2
(M40L and M40I) displayed elevated levels of PB1 early in
infection.
Function of the N40 polypeptide. A recent study suggested
that PB1-F2 influences the intracellular localization of PB1,
since mutations that abolished PB1-F2 expression rendered
PB1 localization more cytoplasmic late in infection (30). Ac-
cordingly, we examined PB1 localization at 8 h p.i. by immu-
nofluorescence in cells infected with our panel of viruses, using
an antiserum that reacted with both full-length PB1 and N40.
As expected, PB1 was concentrated in the nuclei in cells in-
fected with WT virus, although in many cells, some staining
was also apparent in the cytoplasm (Fig. 3D). Similar patterns
were also seen in cells infected with the F2-8, F2-57, M40I, and
M40L viruses. However, after infection with the AUG virus,
PB1 staining was more notably more cytoplasmic, with many
cells showing equal- or higher-intensity staining in the cyto-
plasm than in the nucleus. This latter result is similar to the
phenotype seen by Mazur et al. (30), who also studied viruses
lacking AUG4 and correlated a cytoplasmic shift of PB1 with
FIG. 3. Intracellular localization of PB1-related polypeptides. (A and B) HeLa cells were transfected with plasmids encoding N40, PB1, GFP,
or PA-GFP as indicated; fixed 24 h later; stained with anti-PB1 MAb 10.4; and imaged by confocal microscopy. (C) MDCK cells transfected with
plasmids encoding N40 or (bottom row) empty vector were infected 24 h later with Dk/Sing virus and at 8 h p.i. were fixed and stained with anti-PB1
MAb 10.4 and anti-NP 2915 before imaging by confocal microscopy. (D) MDCK cells were infected with the indicated viruses, fixed, and stained
with anti-PB1 MAb 10.4 at 8 h p.i. Confocal settings were kept consistent throughout each experiment.
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the lack of PB1-F2 expression. However, PB1 staining re-
mained predominantly nuclear in cells infected with the F2-8
virus (Fig. 3D) that is also PB1-F2 null but does not overex-
press N40.
Next, we examined the intracellular localization of N40.
Since N40 lacks the sequences responsible for binding PA (21,
34, 37) and, since PB1 and PA only undergo efficient nuclear
import as a dimer (16, 33), it would be predicted to be largely
cytoplasmic in the absence or presence of PA. To test this, cells
were transfected with plasmids that expressed N40 or the WT
PB1 gene in combinations with either GFP or PA-GFP and
monitored by fluorescence microscopy. Both N40 and PB1
were predominantly (but not exclusively) cytoplasmic in the
absence of other viral proteins, while coexpressed GFP local-
ized throughout the cell (Fig. 3A). PA-GFP was also largely
cytoplasmic when expressed alone but, in combination with
PB1, both polypeptides were concentrated in the nucleus (Fig.
3B). In contrast, when PA-GFP was coexpressed with N40,
both proteins remained mostly cytoplasmic, a finding consis-
tent with their predicted inability to form a stable complex.
PB1 also interacts with PB2 and NP, as well as potentially
forming homo-oligomers (7, 13, 23). Therefore, N40 localiza-
tion in the context of IAV infection was investigated. Since the
N40 product does not contain any unique sequences compared
to PB1, this was achieved by transfecting cells with a plasmid
that expressed the PR8 N40 polypeptide (which reacts with the
anti-PB1 MAb 10.4), followed by superinfection of the cells
with an avian influenza virus (Dk/Sing) whose PB1 lacks the
epitope. Virus-infected cells that had been transfected with
empty plasmid vector stained well for NP but not for PB1,
demonstrating infection and the lack of reactivity of the Dk/
Sing PB1 with the anti-PB1 MAb (Fig. 3C, bottom row). In
uninfected cells, N40 was largely cytoplasmic, as before (top
row). However, in infected cells it localized throughout both
the nucleus and the cytoplasm, indicating partial nuclear up-
take in the presence of other viral proteins. This implies that,
during the course of infection, N40 interacts with another viral
protein(s), resulting in increased nuclear uptake.
Since N40 lacks a PA binding site, it would not be predicted
to be functionally equivalent to PB1, since PA increases the
affinity of PB1 for the vRNA promoter and contains the en-
donuclease activity involved in cap-snatching, and most studies
agree that a trimeric polymerase complex is required for all
forms of viral RNA synthesis (12, 14, 20, 28, 48). Accordingly,
we tested the ability of N40 to support viral gene expression in
an RNP reconstitution assay. Cells were cotransfected with
plasmids encoding PB2, PA, NP, a synthetic vRNA containing
a luciferase reporter gene, and various combinations of N40,
WT PB1, and (to balance plasmid amounts where necessary)
empty vector. In the presence of all four WT RNP proteins, the
vRNA molecule was efficiently transcribed to give rise to large
amounts of luciferase activity, whereas only background
amounts were produced in the absence of PB1 (Fig. 4A). N40
was unable to replace the WT PB1 gene in this system, pro-
ducing background levels of luciferase similar to those of sam-
ples lacking any source of PB1. We also examined whether N40
could act as a trans-dominant inhibitor of the viral polymerase
complex by cotransfecting a 10-fold excess of the N40 expres-
sion plasmid along with the WT RNP components. Although
luciferase accumulation was slightly reduced in the presence of
excess N40, the degree of inhibition was less than that seen
when a similar amount of plasmid vector was cotransfected and
markedly less than the inhibition caused by murine Mx1 (Fig.
4A), used as a known inhibitor of IAV gene expression (5).
Thus, N40 did not support transcriptional activity of the virus
polymerase complex, but neither did it act as a trans-dominant
inhibitor.
These analyses were extended to examine whether the seg-
ment 2 mutations that alter N40 and PB1-F2 expression also
affected transcriptional activity of the RNP complex. RNPs
were reconstituted by plasmid transfection, and luciferase out-
put was measured as described above. All of the segment 2
mutant plasmids supported substantial levels of influenza gene
expression (Fig. 4B). Although the F2-8, F2-57, and AUG
mutants were indistinguishable from WT, the M40L and M40I
genes consistently supported significantly higher levels of lu-
ciferase expression. Thus, in this system, the loss of N40 ex-
pression in the presence of an intact PB1-F2 ORF increases
viral gene expression, whereas the loss of both gene products
leaves it unaltered from WT levels.
FIG. 4. Ability of segment 2 polypeptides to support IAV gene expression. 293T cells were transfected with plasmids encoding PB2, PA, NP,
and a synthetic vRNA analogue containing a luciferase gene along with the indicated combinations of plasmids (WT [WT PB1]) and, 48 h later,
the luciferase activity quantified. The data in panel A are the means 
 the SEM of three independent experiments plotted relative to the activity
seen in the absence of a PB1 gene, whereas the data in panel B are the means 
 the SEM of a minimum of six independent experiments plotted
as the percent activity seen with WT PB1 for each experiment. **, P  0.01.
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To further examine interactions between N40 and the rest of
the viral polymerase components, we turned to the sensitive
technique of examining protein dynamics in live cells by fluo-
rescence recovery after photobleaching (FRAP). We have re-
cently established this system for analysis of the influenza virus
RNP components (25; Loucaides et al., unpublished), based on
a previously described set of GFP-tagged constructs (16).
When the live cell dynamics of nuclear resident PB2-GFP were
examined, the bleached area recovered fluorescence intensity
rapidly and to near 100% of the initial value (Fig. 5A). In
contrast, recovery of the full 3P complex (tagged with PB1-
GFP) was slower and incomplete, indicating the presence of a
substantial immobile fraction. Both recovery curves were
shifted downward in the presence of additional N40, suggesting
a reduction in the mobility of the GFP-tagged components. In
confirmation of this, when the DC values were calculated from
the recovery curves, both PB2-GFP and the full polymerase
complex showed highly significant reductions of 2-fold in
their mobility (Fig. 5C), strongly indicating an interaction with
N40. This interaction was specific, since the recovery curves for
an unrelated cellular nuclear protein, GFP-TAP, were essen-
tially superimposable in the presence or absence of N40 (Fig.
5B) and there was no significant change in DC values (Fig. 5C).
Growth properties of the segment 2 mutant viruses. Overall,
these data indicate that the N40 polypeptide interacts with
other polymerase components and therefore may have an in-
fluence on virus replication. Accordingly, the growth proper-
ties of the segment 2 mutant viruses were examined. When
multicycle replication was examined in MDCK and A549 cells
and in eggs, there was no significant difference in output titer,
as assessed by plaque assay, between the WT virus and any of
the mutants (Fig. 6A and data not shown). However, a minor
but statistically significant difference in plaque size was appar-
ent for the viruses M40L and M40I, which produced plaque
areas ca. 20 to 25% smaller than WT PR8 at 24 h p.i. (Fig. 6B).
This led us to examine the kinetics of virus replication in single
cycle infections in MDCK cells. Under these conditions all
viruses replicated to similar final titers of 108 PFU/ml (Fig.
6C). However, while the kinetics of the F2-8, F2-57, and
AUG viruses were very similar to those of the WT virus, the
M40I and M40L viruses showed a notable delay in replication,
with 100-fold lower titers at 6 h p.i. Both of these viruses
have a mutated PB1 protein, as well as lacking N40 expression.
However, the F2-8 virus, which has the same PB1 mutation as
M40I (and the consequent inability to express N40) but is also
deficient in PB1-F2 expression, showed normal single-cycle
growth kinetics (Fig. 6C). Overall, we conclude that while N40
is clearly not essential for viral growth, its absence, in the
context of an intact PB1-F2 ORF, leads to slower replication
kinetics in cultured cells.
DISCUSSION
We show here the existence of a third polypeptide species
synthesized from IAV segment 2 mRNA. The protein, named
here PB1 N40, is an N-terminally truncated version of PB1 that
arises from translation initiation at AUG5/PB1 codon 40 in the
mRNA, most likely from leaky ribosomal scanning. We base
this conclusion on the observations that the polypeptide reacts
with PB1 antisera whose epitopes are contained between
amino acids 44 to 69 and amino acids 740 to 757 of the full-
length polypeptide, its size (predicted molecular mass of 82
kDa versus 87 kDa for PB1), comigration with recombinant
N40 and, most importantly, the finding that its expression lev-
els vary predictably according to the presence, absence, or
context of AUG5 both in DNA-based and in authentic viral
expression settings. Its expression was detected in a variety of
IAV strains, including representative human, equine, and
avian strains (Fig. 1) and in substantial levels, accounting for 5
to 10% of total PB1 levels in cells infected with WT PR8 virus
FIG. 5. FRAP analysis of N40. 293T cells were transfected with
plasmids encoding PB2-GFP or PB1-GFP, PA, and PB2 (3P) (A) or
GFP-TAP (B) in combination with either N40 or an equivalent
amount of empty vector, and the dynamics of the GFP-tagged proteins
were examined by FRAP. Average (means 
 the SEM) recovery
curves from at least 32 individual cells are plotted in panel A and from
at least 20 cells are plotted in panel B. (C) Mean plus SEM DC values
are plotted. **, P  0.01; ***, P  0.001.
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at 8 h p.i. (Fig. 2). Although (to the best of our knowledge) this
is the first report to systematically define the origin and inves-
tigate the function of this novel addition to the IAV proteome,
our data are compatible with previous studies. Akkina et al.
noted that a variety of IAV strains expressed a slightly shorter
PB1-related polypeptide that was unlikely to be produced by
proteolysis of the full-length protein (1). Perez and Donis also
commented on the presence of an N-terminally truncated form
of PB1 when expression of the gene in transfected cells was
driven by the vaccinia virus/T7 RNA polymerase system (38).
Having identified a 12th primary translation product of IAV,
the important question becomes the function of the protein.
Although N40 contains 718 of the 757 residues present in WT
PB1, the lack of the N-terminal 39 amino acids removes the
sequences defined as the primary interaction site with PA,
which would be expected to result in profound functional dif-
ferences between the two proteins (21, 34, 37). In confirmation
of this, we found that N40 did not form a complex with PA that
was capable of directing efficient nuclear import of the two
proteins (Fig. 3) or support IAV gene expression in an RNP
reconstitution assay (Fig. 4). Overexpression of N40 in the
same system did not lead to trans-dominant inhibition of IAV
gene expression by the WT protein (Fig. 4), and neither was
expression of the N40 gene product essential for virus replica-
tion in tissue culture cells or embryonated eggs (Fig. 6). We
have therefore considered the hypothesis that the N40 protein
has no function in the virus life cycle and is merely an incon-
sequential by-product of PB1-F2 expression operating via
leaky ribosomal scanning and the PB1 gene containing a down-
stream AUG codon. However, several arguments support
more positive hypotheses. First, microscopy of N40 localization
in infected cells showed increased uptake of the protein into
the nucleus (Fig. 3), a finding suggestive of an interaction with
one or more nuclear resident viral proteins other than PA. In
addition to PA, PB1 is known to interact with PB2, NP, PB1-
F2, and itself (7, 13, 23, 30), and while the location of homo-
oligomerization, PB1-F2- and NP-binding domains are not
known, the N40 polypeptide certainly contains the primary
PB2 interaction site (19, 35, 39, 43). Consistent with this,
FRAP analysis of GFP-tagged versions of PB2 and the poly-
merase trimer indicated an interaction with N40 in the nucleus
of cells (Fig. 5). Second, mutations that affected the production
of N40 revealed a complex interdependence of the expression
kinetics of the three proteins translated from segment 2
mRNA (Table 1). Although the observation that loss of the
PB1-F2 AUG in the AUG virus upregulates translation of
the downstream initiating AUG of N40 is readily explainable,
the finding that the same mutation leads to decreased PB1
accumulation at early times p.i. (Fig. 2C) was unexpected.
Similarly, the3-fold difference in PB1 levels at 4 h p.i. during
infection with the M40I and F2-8 viruses (Fig. 2D), both of
which contain the same mutation in PB1 that abolishes N40
expression but which differ in the presence or absence of an
intact PB1-F2 ORF, respectively, is further evidence that ex-
pression of the three polypeptides is not independent. In all
cases however, PB1 accumulation balanced out to near-normal
levels later in infection. To what extent this interdependence
(and the changing relative proportions of N40 and PB1 accu-
mulation during infection with WT virus) results from transla-
tional mechanisms and/or the differential stability of the three
proteins remains to be determined. The data indicating a phys-
ical interaction between PB1 and PB1-F2 (30) and a study
suggesting that PB1 abundance is regulated by additional fac-
tors than simply the poor Kozak consensus of AUG1 (29) are
consistent with both possibilities. Third, the loss of N40 expres-
sion in the presence of an intact PB1-F2 gene leads to a
replication defect in MDCK cells (Fig. 6). The overlapping/
coincident nature of the PB1, PB1-F2, and N40 ORFs prevents
the design of “clean” mutations that affect the structure and
expression of only one protein at a time, but this conclusion
can safely be drawn from comparing the behavior of the F2-8,
M40I, and M40L viruses. While the slow replication kinetics of
FIG. 6. Growth properties of segment 2 mutant viruses. (A) Titers
achieved at 48 h p.i. in MDCK cells infected at an MOI of 0.01 or at
48 h p.i. from eggs inoculated with 1,000 PFU are plotted. The means
plus the ranges of two independent experiments are shown. (B) Mean
plus SEM plaque areas in MDCK cells at 24 h p.i. are plotted. At least
150 plaques were measured from three separate experiments, and the
data were normalized with respect to the mean plaque area of a
matching WT virus. ***, P  0.001. (C) Single cycle growth curves
from MDCK cells infected at an MOI of 3. The means plus the SEM
of four independent experiments using a minimum of two separate
virus isolates are plotted.
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the M40L virus could perhaps be attributed to its eponymous
PB1 mutation, the M40I and F2-8 viruses again provide a
matched comparison: they contain the same PB1 mutation, the
same deficit in N40 synthesis but differ in their respective
ability or inability to express PB1-F2. The former virus that
expresses two of the three segment 2 polypeptides, PB1 and
PB1-F2, grew slowly, while the latter virus, which expresses
only PB1, grew normally. We also note that whereas the vast
majority of natural IAV isolates have PB1 M40, the small
number that do not, possess either an isoleucine or a leucine
residue (Table 2). Multiple IAVs with a PB1 M40I mutation
(similar to our F2-8 virus) were isolated from a variety of avian
species in the South China area (46), ruling out the possibility
of sequencing errors. Furthermore, all known influenza virus B
and C PB1 proteins have an isoleucine or leucine residue,
respectively, at position 40, overall suggesting that a methio-
nine is not obligatory for polymerase function. Thus, we have
two current working hypotheses: first, that N40 expression has
no direct functional relevance per se but is indirectly important
in maintaining the correct balance between PB1 and PB1-F2
expression. In this regard, it is interesting that of the 26 natural
virus isolates lacking the N40 AUG codon, only three possess
a long (78-amino-acid) PB1-F2 ORF that includes the mito-
chondrial targeting sequence, and of these, one virus has al-
terations to two amino acid residues shown to be important for
mitochondrial localization (47), while a third has the W9L
mutation that in PR8 M40I reduced the steady-state abun-
dance of the protein (Table 2 and Fig. 2A and E). A second
hypothesis, not incompatible with the first, holds that the N40
protein has a nonessential and as-yet-undetermined function in
virus replication. Further work is necessary to test these pro-
posals.
Whether or not the N40 product has a positive function in
the virus life cycle, our finding that mutations of the type used
in several prior studies to investigate the role of PB1-F2 affect
its expression and that of PB1 is important. Elucidation of the
function of PB1-F2 has not been straightforward. Although all
studies in which segment 2 has been mutated to block PB1-F2
expression agree that the protein is not essential for virus
replication in tissue culture, eggs, or mice, various phenotypes
have been observed for the PB1-F2 null viruses. These pheno-
types range from apparently unaltered replication kinetics in
any tested system to both slight increases and decreases in
growth parameters in MDCK cells, along with a general but
not consistent tendency to reduce pathogenicity in mice (9, 30,
31, 50). However, we note that the original publication on
PB1-F2 (9) relied in part for its conclusions on a virus in which
the N40 AUG had been mutated (similar to our F2-8 virus),
thus blocking expression of N40, as well as full-length PB1-F2.
Moreover, all of the studies examining PB1-F2 null viruses that
we are aware of used, at least in part, viruses in which the
PB1-F2 AUG had been mutated, which is analogous to our
AUG virus. Our data predict that these viruses will similarly
overexpress the N40 product. If this is indeed the case, some
aspects of these data may be open to reinterpretation, at least
until the role of N40 is better defined. As a case in point, while
our data showing increased cytoplasmic staining with a PB1
antibody after infection with the AUG virus (Fig. 3) recapit-
ulates a previous study (30) with an equivalent virus, the fact
that we did not see a similar outcome with other PB1-F2
deletion viruses, coupled with the observation that only the
AUG virus expresses much higher levels of the largely cyto-
plasmic N40 protein, strongly argues that, at least for our virus,
the cytoplasmic species is in fact the shorter form of PB1.
To summarize, we have shown that three, not two, of the
5-proximal AUG codons in segment 2 mRNA direct transla-
tion initiation, resulting in the expression of not only the pre-
viously defined PB1 and PB1-F2 polypeptides but also a novel
PB1 variant, PB1 N40. The function of the N40 polypeptide
remains to be defined, but the overlapping nature and appar-
ent translational interdependence of the segment 2 cistrons
makes it potentially very difficult to disentangle the relative
contributions of the three protein products to viral replication
and pathogenicity. Recent studies in which virulence has been
correlated with PB1-F2 sequence polymorphisms well down-
stream of the ribosomal initiation sites in the mRNA provide
compelling evidence for the importance of PB1-F2 (10, 31)
even in light of the findings reported here. Nevertheless, we
would argue that further work is necessary to fully understand
the contributions the segment 2 gene products make to IAV
pathogenicity.
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